Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sex-determining region Y protein (SRY) is a DNA-binding transcription factor encoded by the SRY gene on the Y chromosome and is crucial for initiating male sex determination in therian mammals[1][2]. SRY upregulates SOX9 expression in the bipotential gonad, triggering Sertoli cell formation, which leads to the development of testes and subsequent male differentiation[1][2][3][4][5][6]. In the absence or mutation of SRY, an XY individual can develop as phenotypically female, while aberrant presence or activation in XX individuals can result in male traits[1][3]. SRY acts primarily during early fetal development and belongs to the SOX (SRY-box) gene family, with its sequence-specific HMG domain mediating DNA binding and bending[1][5][6]. Mutations in SRY's HMG domain are a major cause of XY sex reversal and disorders of sex development in humans[1][3][6]. SRY is not considered a traditional therapeutic target, as its critical role is limited to development and not subject to pharmacological modulation[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sex-determining region Y protein (SRY).